Polycythemia vera, management approaches

Abdulmajeed Mualla M Alotaibi, Kholod Khalid A Aljaberi, Khlood Mohammed M Assiri, Ammar Adnan S Almaghrabi, Bayan Atiah Allah D ALMabadi, Zainab Abduljabbar Al Hamoud, Noor Khalid Abdulrazaq ALJarba, Mona Ali H Alrashed, Feras Abdulwahab M Alghamdi

v Abstract

Polycythemia vera (PV) is currently identified as one of the three classic, Bcr/Abl- adverse, myeloproliferative disorders (MPD), together with important thrombocythemia (ET) and also myelofibrosis with myeloid metaplasia (MMM). It is now well-established that PV stands for a clonal stem-cell process that is identified by trilineage myeloproliferation, splenomegaly, thrombohemorrhagic difficulties, aquagenic pruritus, and a propensity for clonal advancement into either acute myeloid leukemia (AML) or MMM . Typical age at diagnosis is approximately 60 years and also typical life expectancy with contemporary therapy methods 20 years . The latter represents a significant renovation over historic controls, where premature death from thrombotic difficulties reduced survival to a median of less than 2 years . Present agreement debts the restorative use of hostile phlebotomy as being largely responsible for this remarkable change in survival. Nevertheless, the antithrombotic value of phlebotomy has actually not been appropriately assessed in a controlled setting, whereas randomized clinical tests have actually shown substantial reduction in vascular occasions when phlebotomy was supplemented with either myelosuppressive therapy or low-dose aspirin. In conlcusion , Physicians have for many years relied upon dimension of the RCM for the diagnosis of PV. Quantitative reference varieties are utilized to define normality, as a needed examination for the diagnosis of PV. To date, no systematic evidence sustains such technique as well as novel diagnostic assays, which are based upon disease biology, are being created and also their clinical energy verified.

· Introduction

Polycythemia vera (PV) is currently identified as one of the three classic, Bcr/Abl- adverse, myeloproliferative disorders (MPD), together with important thrombocythemia (ET) and also myelofibrosis with myeloid metaplasia (MMM). It is now well-established that PV stands for a

clonal stem-cell process that is identified by trilineage myeloproliferation, splenomegaly, thrombohemorrhagic difficulties, aquagenic pruritus, and a propensity for clonal advancement into either acute myeloid leukemia (AML) or MMM[(1)]. Typical age at diagnosis is approximately 60 years and also typical life expectancy with contemporary therapy methods 20 years [(2)]. The latter represents a significant renovation over historic controls, where premature death from thrombotic difficulties reduced survival to a median of less than 2 years [(3)]. Present agreement debts the restorative use of hostile phlebotomy as being largely responsible for this remarkable change in survival. Nevertheless, the antithrombotic value of phlebotomy has actually not been appropriately assessed in a controlled setting, whereas randomized clinical tests have actually shown substantial reduction in vascular occasions when phlebotomy was supplemented with either myelosuppressive therapy [(4)] or low-dose aspirin [(5)].

Current dogma takes into consideration a hematocrit degree (Hct) of 45% as the uppermost permitted range before employing upkeep phlebotomy in patients with PV. There is no controlled proof to sustain this certain referral as well as a substantial minority of Swedish and american hematologists utilize a target Hct that comes close to 50%[(6,7)]. Regardless, the administration of boosted Hct secondary to PV in terms of both treatment seriousness and certain treatment is sharply different from the handlement of a non-clonal increase in Hct[(4,8)]. This is since although there are periodic records of boosted vascular complications attached to both loved one as well as second polycythemia, the thrombogenic possibility of a non-clonal boost in Hct is typically believed to be considerably much less compared to that of PV[(9)]. As necessary, prompt establishment of therapeutic phlebotomy for second polycythemia is not constantly necessary, as well as might also be detrimental in specific circumstances[(10)]. In enhancement, the Hct target, if phlebotomy is suggested for additional polycythemia, is established at a higher level. The main concern during the assessment of 'polycythemia' is whether one is dealing with PV.

v Methodology

The databases of PubMed, the Cochrane library, EMBASE, Chinese Biomedical Database and ISI Web of Knowledge were searched up to July 2016 without language and publication status restrictions. The search strategies included the following terms[Mesh]: “bone marrow”, “red cell mass”, “erythropoietin”, “polycythemia”. In addition, Google scholar and the lists of references were also searched for other relevant RCTs.

v Results and Discussion

THE DIFFERENTIAL DIAGNOSIS OF POLYCYTHEMIA VERA

In regular clinical technique, PV is normally presumed when an offered Hct exceeds the ceilings of the recommendation array, readjusted for sex as well as race. The assumption of an increased Hct may (real polycythemia) or might not (apparent polycythemia) be connected with a real rise in the complete intravascular red blood cell material, likewise understood as the red cell mass (Table 1).

Table 1. Classification of ‘polycythemia’.
Apparent polycythemia
Relative polycythemia8
Extreme ‘high normal’ values30
True polycythemia
Polycythemia vera1
Secondary polycythemia
Congenital

True polycythemia

True polycythemia stands for a rise in either clonal (polycythemia vera) or non-clonal (second polycythemia) erythropoiesis (Table 1). In PV, the enhanced red blood cell (RBC) manufacturing is neither moderated by erythropoietin (Epo) [(11)] neither related to an activating anomaly of the Epo receptor (EpoR)[(12,13)]. By contrast, enhanced Epo manufacturing characterizes a big fraction of the conditions that are connected with additional polycythemia (SP). For sensible purposes, SP can be classified right into genetic and also acquired categories (Table 1). Genetic polycythemia might or may not be associated with raised lotion Epo degrees. Both Chuvash polycythemia connected with von Hippel-Lindau (VHL) gene mutation14 and high oxygen-affinity hemoglobinopathies/enzymopathies[(15,16)] are linked with boosted or regular serum Epo levels. In contrast, genetic polycythemias connected with EpoR mutations[(17)] are associated with low product Epo degrees.

Acquired SP is triggered by a myriad of pathological conditions that could or could not be connected to Epo overproduction. The hypoxic stimulation for Epo-mediated gotten SP is usually central, with cardiopulmonary conditions being one of the most accountable[(18)]. Other reasons for main hypoxia include high-altitude habitat[(19)] and carbon monoxide poisoning[(20)]. Peripheral tissue hypoxia from kidney artery constriction could likewise be connected with Epo-mediated SP[(21)]. On the other hand, the role of either hypoxia or Epo arbitration in SP connected with either smoking [(22)] or rest apnea[(23)] has not been completely made clear. Abnormal manufacturing of Epo may also happen in the absence of a hypoxic stimulus, as in tumor-associated polycythemia[(24,25)]. Exogenous management of medicines such as Epo or androgen prep work have additionally been implicated in acquired SP[(26,27)]. In the absence of a recognizable reason, real polycythemia has actually been designated as idiopathic erythrocytosis[(28)]. Nevertheless, a significant variety of patients with the latter entity could stand for very early PV, hereditary polycythemia, or occult SP[(29)].

Apparent polycythemia

Apparent polycythemia (AP) results from either a reduction in plasma quantity (relative polycythemia) or one's misperception of what comprises the ceiling of typical worths for Hct[(30)]. On top of that, AP consists of instances that represent the appropriate tail of the Gaussian distribution for typical Hct worths (i.e. the 2.5% of the typical population whose Hct worths exceed

the ceilings of the referral array). Acute circumstances of relative polycythemia consisting of serious dehydration from several reasons are commonly scientifically obvious. On the other hand, some detectives have actually doubted the presence of a nosologic entity defined by a constantly acquired plasma volume[31-34]. Here, both 'Gaisbock syndrome' (family member polycythemia connected with hypertension and also nephropathy) [35] and 'stress and anxiety polycythemia' (family member polycythemia associated with emotional stress) [36] are inadequately recognized concepts in which tightening of the vascular area is thought to play a part[8,37]. The issue is further dumbfounded by reports of raised morbidity and death connected with 'persistent relative polycythemia'[38].

RED CELL MASS MEASUREMENT IN POLYCYTHEMIA VERA

The total blood quantity (BV) generally makes up around 7% of the body weight and is composed of the RCM (i.e. volume occupied by red blood cells) and plasma volume. In regular clinical practice, RCM is estimated indirectly from 3 quantitative research laboratory specifications consisting of venous Hct (i.e. jam-packed cell quantity), hemoglobin, and RBC count. These specific dimensions are all influenced by modifications in plasma quantity and for that reason do not necessarily provide a precise estimate of the intravascular red cell web content. Moreover, splenomegaly, when present, modifies the total circulation of RBC in relation to plasma and also subsequently influences the Hct[39] Such are the problems that partially underlie the reasoning to go after option, 'straight' approaches of RCM quantitation to examine polycythemia.

Background

The principle of BV measurement is based upon the sign dilution method initially presented in 182940 and consequently utilized to estimate blood circulation as well as BV in 1897[41]. Start in 1915[42] and also using the important red method, a significant amount of work from several private investigators developed the sign dilution approach as an approved lab examination for BV dimensions[43,44] Modern techniques of BV measurement usage, as the indication, radioactively classified RBC (e.g.51Cr-tagged) or albumin (e.g. 125I-tagged), to measure complete BV as well as plasma volume, respectively[45]. The results are revealed in referral either to body mass or to account for body fat, which is avascular-body surface area[46].

There are 2 schools of thought concerning making use of BV dimensions to determine RCM. In one, RCM is acquired by subtracting the plasma quantity determined by 125I-tagged albumin

approach from the total BV measured by the 51Cr-tagged erythrocyte technique, done simultaneously[47]. In the other, RCM is calculated by multiplying plasma quantity gauged by 125I-tagged albumin approach with a formula which contains venous Hct remedied to show body Hct[48,49]. The supporters of the previous technique suggest that the body Hct could not be properly computed from the venous Hct however fail to appreciate that the more comprehensive issue with RCM dimension, in the diagnosis of PV, has little to do with the computation of body Hct.

Methodological and other limitations

In general, BV measurements, no matter just what formula one makes use of to compute RCM, are prone to multiple levels of imprecision, consisting of errors from pipetting, counting, calibration, and variants in blending time and also instrumentation[47,50]. Not all of these step-by-step actions are very easy to systematize as well as demand a high level of quality-control systems that could not be inexpensive for lots of laboratories. Also if one handles to measure RCM accurately, analysis of the result needs understanding of a specific baseline value that is gotten under comparable circum-positions[49,51]. Clearly this is an unwise situation as well as the present method of making use of population-based reference ranges weakens the art of choice analysis for the specific patient. It is similarly essential to bear in mind that obesity, which is an existing epidemic in established nations, stays a significant confounding factor in outcome analysis of RCM, despite the various techniques made use of to make up for body structure[52].

What is the diagnostic accuracy of red cell mass measurement in polycythemia vera and is the information from the specific test of additional value?

The analysis utility of RCM dimension was backed, with no organized supportive evidence, based upon a collection of qualification requirements for a clinical trial formulated by an international Polycythemia Vera Study Group (PVSG) in 1967[53]. It was promptly clear, even after that, that RCM measurement could not differentiate between PV and SP and also for that reason had to be supplemented by extra information, consisting of splenomegaly and also other features of clonal myeloproliferation. However, the particular actions utilized here made use of an insufficient set of organic info with succeeding compromise in examination sensitivity[54]. As a whole, the absence of a gold criterion, akin to the Philadelphia translocation in persistent myeloid leukemia, had prevented correct examination of analysis procedures in PV.

The diagnostic accuracy of RCM dimension was lately examined in a successive mate of 105 patients with both clonal as well as non-clonal 'polycythemia' along with ET, in which analysis groups were developed based on both retrospective and possible evaluations of clinical information, bone marrow histology, as well as other essential lab parameters. BV was gauged by a semi-automated system that uses 131I-tagged human product albumin and RCM was figured out using whole body hematocrit[34]. Results were shared in reference to body surface as well as analyzed complying with the published recommendations of the ICSH[46]. RCM measurement had 76% level of sensitivity in the diagnosis of PV, as well as 79% specificity in distinguishing PV from AP. Moreover, in none of the patients with PV was the details from RCM measurement found to be of added analysis worth. The observations from this study underscore that PV is a biological and not a measurable entity, and that it is related to distinct bone marrow histological functions that have actually been conspicuously ignored as analysis devices[55,56].

SPECIALIZED TESTS FOR THE DIAGNOSIS OF POLYCYTHEMIA VERA

Polycythemia rubra vera-1 assay

Polycythemia rubra vera-1 (PRV-1) belongs to the UPAR receptor superfamily[57,58]. In humans, PRV-1 is precisely shared in the fetal liver and bone marrow; namely in megakaryocyte precursors as well as cells of myeloid beginning[57]. Given that the initial summary of the upregulation of neutrophil PRV-1 expression in PV[57], the incident of a comparable sensation has been demonstrated, at variable rates, in other myeloid malignancies including ET,[59-67] MMM,[57,59,67] chronic myeloid leukemia (CML),[57,59,67,68] AML,[57] and also myelodysplastic syndrome (MDS)[59,67,68]. In addition, neutrophil PRV-1 expression has been examined in a number of responsive conditions, including SP, responsive thrombocytosis, as well as second leukocytosis[59,62,64,65,67,68]. Generally, these research studies have divulged a solid organization in between neutrophil PRV-1 overexpression and also PV that is neither invariable (examination sensitivity varies from 69 to 100%) [57,63,64,66,67] nor special (a substantial minority of patients with MMM along with 17-67% of patients with ET additionally show the specific abnormality)[59,63,64,67].

At first, PRV-1 expression was measured semi-quantitatively by either Northern blot analysis57 or RT-PCR[59]. Subsequently, a real-time RT-PCR method was developed [62] as well as this

measurable assay has actually considering that been used extensively[62-68]. The last technique was made use of most recently in two huge studies involving an overall of 235 patients with Philly-adverse MPD in one [67] and 142 patients with both regular and also atypical MPD in the other study. Both research studies verified the suboptimal performance of the PRV-1 assay when it come to PV diagnosis with examination level of sensitivity and specificity that ranged from [68-76] to 60-85%, specifically.[67] These two research studies likewise confirmed the event of boosted neutrophil PRV-1 expression in a variable percentage of patients with both atypical as well as typical MPD. One of the two studies showed a medically valuable relationship in between PRV-1 expression and leukocyte alkaline phosphatase (LAP) score that increased the issue of added worth relating to consideration of the specific assay as a new analysis test.

Platelet-rich plasma serotonin assay

Blood serotonin is stored in the dense bodies of megakaryocytes and platelets[69,70]. The content of these dense bodies, including that of serotonin, has been shown to be decreased in patients with MPD[71]. Intraplatelet serotonin content is readily measured by various conventional laboratory methods, including enzyme-linked immunosorbent assay (ELISA) and fluorescence-based immunocytochemical assay[72,73]. The use of such assays has disclosed a significant difference in platelet serotonin content between ET and reactive thrombocytosis[74,75]. Based on these preliminary data, an ELISA-based evaluation of platelet-rich plasma (PRP) serotonin concentration was studied in a prospective study of 109 subjects with PV, ET, MMM, and SP.

[76]. The results disclosed, in the absence of active therapy with a selective serotonin reuptake inhibitor, markedly decreased PRP serotonin levels in MMM and PV with minimal overlap of values compared to either normal controls or patients with SP. PRP serotonin levels were also significantly less in patients with ET but a few patients displayed normal values as well. In the particular study, PRP serotonin measurement performed better than the PRV-1 assay in distinguishing PV from SP (93 versus 86% test accuracy)[76].

Endogenous erythroid colony growth assay

Endogenous (spontaneous, growth factor-independent) artificial insemination erythroid colonies (EEC) are not seen in either normal subjects or reactive myeloproliferation[77]. The certain

phenomenon is mainly seen in PV [(78)] yet can additionally be seen in a proportion of patients with either ET [(79)] or MMM[(79)]. For that reason, the particular assay cannot compare PV and also ET yet lugs a high degree of favorable predictive worth for detecting PV as opposed to SP[(80-83)]. Nonetheless, an adverse test does not always omit the diagnosis of PV as well as the inconsistency in the literary works in relation to examine level of sensitivity might not, necessarily, be attributed to technical differences[(84)].

Megakaryocyte/platelet Mpl expression

The sensation of a significant decline in megakaryocyte/platelet Mpl expression wasted initially reported in ET[(85)] and later on in PV86 as well as other MPD[(87)]. Subsequent research studies exposed marked heterogeneity, amongst PV patients, of Mpl expression in numerous cell kinds, consisting of myeloid progenitors, megakaryocytes, as well as platelets.88- 90 Furthermore, a current study contrasted the performance of the Mpl assay to that of EEC as well as PRV-1 with reported examination sensitivities of 30, 100, and 91%, respectively[(63)]. As a result, it is unlikely that the particular assay will certainly play a significant duty in PV diagnostics.

The JAK2V617F tyrosine kinase mutation

Several groups have separately explained the frequent incident of an obtained JAK2V617F mutation in PV, ET, MMM in addition to less regularly in atypical MPD and MDS[(91-97)]. In one study specifically, where an extremely sensitive allele-specific PCR strategy was used, the details mutation was reported to be present in granulocytes from 71 of 73 PV patients (97%) however absent in all 90 controls tested[(91)]. In a survey of six research studies, where the specific mutation was examined in traditional MPD, the mutational frequencies varied from 65 to 97% in PV, 23-57% in ET, and also 35-57% in MMM[(91-95,97)]. To date, JAK2V617F has not been discovered in regular controls. Nonetheless, a range of irregular MPD also display JAK2V617F in a minority of damaged patients. Therefore, mutation screening for JAK2V617F would certainly have neither the sensitivity neither specificity to differentiate PV from various other MPD. On the other hand, its prospective analysis utility in distinguishing PV from SP was recommended by 2 other researches that showed the absence of the anomaly in additional erythrocytosis[(92,93)].

A DIAGNOSTIC ALGORITHM FOR POLYCYTHEMIA VERA

When should polycythemia vera be suspected?

Although PV is typically believed in the presence of an 'enhanced' venous Hct, the diagnosis has to be captivated in the presence of PV-characteristic clinical attributes (e.g. a thrombotic occasion, aquagenic pruritus, splenomegaly, erythromelalgia or various other symptoms of acral ischemia, leukocytosis, thrombocytosis, or microcytosis that relates to iron shortage) also when the Hct is within the 'typical variety', because reference varieties do not take individual standard worths into account. This is particularly crucial when it comes to inapparent polycythemia, when the Hct may show up typical regardless of the presence of an increased RCM from PV, as a result of a concomitant increase in plasma quantity connected with marked splenomegaly[(98)]. The diagnosis of PV should likewise be taken into consideration in the presence of a documented rise in a person's Hct from standard no matter the outright worth. Because such possible changes from baseline are biologically essential and are not constantly detected by a referral range-based metrics system, this is. It is this extremely principle that has actually thwarted acknowledgment by advocates of the RCM measurement for the diagnosis of PV.

Initial laboratory tests for suspected polycythemia vera

The very first line collection of tests for the analysis assessment of PV must include serum Epo level and LAP score. A high serum Epo level makes the diagnosis of PV extremely not likely[(99,100)]. In one recent research study, none of 99 patients with PV presented an increased serum Epo level[(100)]. By contrast, a reduced serum Epo degree is very suggestive of the diagnosis (test sensitivity and specificity over 90 as well as 95%, specifically) and also mandates bone marrow examination[(99,100)]. A good personal as well as family history ought to deal with the fighting chance of genetic polycythemia connected with an Epo receptor anomaly, which could also be associated with a reduced serum Epo level[(17)]. A 'normal' lotion Epo neither eliminate the possibility of PV neither necessarily mandates bone marrow examination[(99,100)]. In such an instance, bone marrow examination is recommended only in the visibility of either a raised LAP score or a PV- particular attribute .

Bone marrow examination is the most useful laboratory test for confirming a diagnosis of polycythemia vera and often obviates the need for specialized biological assays

A bone marrow exam, when suggested inning accordance with referrals detailed in previous sections, must constantly be accompanied by cytogenetic researches. Particular bone marrow

histological attributes of PV include both numerical as well as morphological abnormalities of megakaryocytes consisting of cluster formation, increased reticulin fibrosis, and bone marrow hypercellularity[56]. Cytogenetic irregularities are identified in just 13-18% of situations with PV at diagnosis and are therefore not really helpful for analysis functions[101]. Regardless, in the visibility of an experienced clinical hematopathologist, the distinction between PV and also non-clonal polycythemia is usually secured by the exam of the bone marrow histology and making use of specialized diagnostic assays, here, is hardly ever required.

The analysis worth of bone marrow examination in PV is greatly boosted by adding cytogenetic research studies and also anomaly testing for JAK2V617F . The data from the abovementioned studies plainly established a web link in between JAK2V617F as well as bcr/ abl-negative, timeless MPD[91-95,97]. So far, the particular mutation appears to occur in the majority of patients with PV along with in a substantial percentage of those with either ET or MMM. Two other studies have actually shown the infrequent (0-25%) event of JAK2V617F in atypical MPD as well as MDS[96,97]. By contrast, JAK2V617F, today, has not been found in either regular controls or patients with additional erythrocytosis.

Numerous research studies are currently continuous to verify the results of the abovementioned research studies on JAK2V617F. Based on existing info, the research laboratory detection of JAK2V617F, either in bone marrow or outer blood myeloid cells, is very suggestive of a clonal MPD as opposed to responsive myeloproliferation such as second erythrocytosis. Therefore, anomaly screening for JAK2V617F ought to give added diagnostic details within the context of current analysis algorithms for PV and also ET . Ultimately, the currently readily available specialized organic assays in PV are not extensively readily available for routine clinical use as well as their interpretation in an individual patient need to always remain in the context of other clinical and laboratory findings.

· Conclusion

Physicians have for many years relied upon dimension of the RCM for the diagnosis of PV. Quantitative reference varieties are utilized to define normality, as a needed examination for the diagnosis of PV. To date, no systematic evidence sustains such technique as well as novel diagnostic assays, which are based upon disease biology, are being created and also their clinical

energy verified. At the same time, RCM measurement is a technically requiring procedure that is tough to standardize as well as several research laboratories have abandoned the test. Rather, most of hematologists utilize a mix of lotion erythropoietin level as well as bone marrow histology making a working diagnosis of PV[(102)]. Throughout the years, the yearly regularity of RCM examination getting at the Mayo Center has decreased from over 400 per year to the existing level of less than 10 annually. There is no proof that this modification in practice has resulted in either a lower yearly occurrence of situations seen or enhanced disease morbidity. Rather, a recent retrospective study from the exact same institution divulged suboptimal diagnostic precision connected to RCM dimension regardless of the utilization of contemporary techniques of outcome interpretation. No matter, it is just a matter of time prior to an unquestionable molecular pen for PV is determined and the controversy over RCM dimension ends up being immaterial. Additional assistance for this contention is offered by the current summary of an MPD-specific JAK2 anomaly (JAK2V617F), which occurs most of patients with PV but not in those with various other causes of polycythemia[(91-94)].

References

1. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings 2003; 78: 174–194.

2.Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medical 2004; 117: 755–761.

3.ChievitzE&ThiedeT.Complicationsandcausesofdeathinpolycythemiavera.ActaMedicaScandinavica 1962; 172: 513–523.

4.Berk PD, Wasserman LR, Fruchtman SM & Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In Wasserman LR et al (ed.) Polycyhtemia Vera and the Myeloproliferative Disorders. London: W. B. Saunders, 1995, pp. 166–194.

5.LandolfiR,MarchioliR,KuttiJetal.Efficacyandsafetyoflowdoseaspirininpolycythemiavera.TheNew England Journal of Medicine 2004; 350: 114–124.

6.Streiff MB, Smith B & Spivak JL. The diagnosis and management of polycythemia vera in the era since the polycythemia vera study group: a survey of american society of hematology members' practice patterns. Blood 2002; 99: 1144–1149.

7.Andreasson B, Lofvenberg E & Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. European Journal Haematology 2005; 74: 489–495.

8.Isbister JP. The contracted plasma volume syndromes (relative polycythaemias) and their haemorheological significance. Baillieres Clinic Haematology 1987; 1: 665–693.

9.Schwarcz TH, Hogan LA, Endean ED et al. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. Journal of Vascular Surgery 1993; 17: 518–522.

10.Ammash N & Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. Journal of the American College Cardiology 1996; 28: 768–772.

11.Fisher MJ, Prchal JF, Prchal JT & AD DA. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982–1991.

12.Le Couedic JP, Mitjavila MT, Villeval JL et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 1996; 87: 1502–1511.

13.Means Jr. RT, Krantz SB, Sawyer ST & Gilbert HS. Erythropoietin receptors in polycythemia veraJournal of Clinical Investigation 1989; 84: 1340–1344.

14.Ang SO, Chen H, Hirota K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genetics 2002; 32: 614–621.

15.Moo-Penn WF, Schneider RG, Shih T et al. Hemoglobin Ohio (beta 142 Ala replaced by): a new abnormal hemoglobin with high oxygen affinity and erythrocytosis. Blood 1980; 56: 246–250.

16.Hoyer JD, Allen SL, Beutler E et al. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. American Journal of Hematology 2004; 75: 205–208.

17.Sokol L, Luhovy M, Guan Y et al. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995; 86: 15–22.

18.Tyndall MR, Teitel DF, Lutin WA et al. Serum erythropoietin levels in patients with congenital heart disease. The Journal of Pediatrics 1987; 110: 538–544.

19.MilledgeJS&CotesPM.Serumerythropoietininhumansathighaltitudeanditsrelationtoplasmareni n. Journal of Applied Physiology 1985; 59: 360–364.

20.DiMarco AT. Carbon monoxide poisoning presenting as polycythemia. The New England Journal of Medicine 1988; 319: 874.

21.CoulthardMG&LambWH.Polycythaemiaandhypertensioncausedbyrenalarterystenosis.Archiv esof Disease in Childhood 2002; 86: 307–308.

22.Tanabe N, Ohnishi K, Fukui H & Ohno R. Effect of smoking on the serum concentration of erythropoietin and granulocyte-colony stimulating factor. Internal Medicine 1997; 36: 680–684.

23.Hoffstein V, Herridge M, Mateika S et al. Hematocrit levels in sleep apnea. Chest 1994; 106: 787–791.

24.SamynI,FontaineC,VanTussenbroekFetal.Paraneoplasticsyndromesincancer:Case1.Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. Journal of Clinical Oncology 2004; 22: 2240–2242.

25.Drenou B, Le Tulzo Y, Caulet-Maugendre S et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouvelle Revue franc¸aise d'He´matologie 1995; 37: 197–199.

26.Rhoden EL & Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 2004; 350: 482–492.

27.Jelkmann W. Erythropoietin. Journal of Endocrinological Investigation 2003; 26: 832–837.

28.Pearson TC & Messinezy M. Idiopathic erythrocytosis, diagnosis and clinical management. Pathologie Biologie (Paris) 2001; 49: 170–177.

29.Blacklock HA & Royle GA. Idiopathic erythrocytosis—a declining entity. British Journali of Haematology 2001; 115: 774–781.

30.Fairbanks VF & Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults:relevance to apparent polycythemia. European Journal of Haematology 2000; 65: 285–296.

31. Fair banks VF.Myeloproliferativedisease: polycythemiavera:thepackedcellvolumeandthecuriouslogic of the red cell mass. Hematology 2000; 4: 381–395.

32.BrownSM,GilbertHS,KraussSetal.Spurious(relative)polycythemia:Anon-existentdisease.American Journal of Medicine 1971; 50: 220–227.

33.Fessel WJ. Odd men out: individuals with extreme values. Archives of Internal Medicine 1965; 115: 736– 737.

34.Fairbanks VF, Klee GG, Wiseman GA et al. Measurement of blood volume and red cell mass—reexamination of Cr-51 and I-125 methods (corrected version of Vc666). Blood Cells Molecules and Diseases 1996; 22: 169–186.

35.GeisbockF.DieBedeutungderBlutdruckmessungfurdiePraxis.ArchivesClinicalMedicine(Leipzig)1905; 83.

36.LawrenceJH&BerlinNI.Relativepolycythemia-thepolycythemiaofstress.TheYaleJournalofBiologyand Medicine 1952; 24: 498–505.

37.Bentley SA & Lewis SM. The relationship between total red cell volume, plasma volume and venous haematocrit. British Journali of Haematology 1976; 33: 301–307.

38.BurgePS,JohnsonWS&PrankerdTA.Morbidityandmortalityinpseudopolycythaemia.Lancet1975;1: 1266–1269.

39.JonssonV,BockJE&NielsenJB.Significanceofplasmaskimmingandplasmavolumeexpansion.Journalof Applied Physiology 1992; 72: 2047–2051.

40.Hering E. Versuche, die Schnelligkeit des Blutlaufs und der Absonderung zu Bestimmen. The Journal of Physiology 1829; 3: 85–126.

41.Stewart GN. Researches on the circulation time and on the influences which affect it IV. The output of the heart. The Journal of Physiology 1897; 22.

42.Keith NM, Rowntree LG & Geraghty JT. A method for the determination of plasma and blood volume. Archives of Internal Medicine 1915; xvi: 547–557.

43.Hamilton WF, Moore JW, Kinsman JM & Spurling RG. Simultaneous detrmination of the pulmonary and systemic circulation times in man and of a figure related to cardiac output. American Journal of Physiology 1928; 84: 338–344.

44.Rowntree LG, Brown GE & Roth GM. Volume of Blood and Plasma in Health and Disease. London: W B Saunders; 1929.

45.Wright RR, Tono M & Pollycove M. Blood volume. Seminars in Nuclear Medicine 1975; 5: 63–78.

46.PearsonTC,GuthrieDL,SimpsonJetal.Interpretationofmeasuredredcellmassandplasmavolumein adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. British Journal of Haematology 1995; 89: 748–756.

47.Standard techniques for the measurement of red-cell and plasma volume. A report by the international committee for standardization in hematology (ICSH): panel on diagnostic applications of radioisotopes in haematology. British Journal of Haematology 1973; 25: 801–814.

48.Balga I, Songthaew M & Furlan M. Should whole-body red cell mass be measured or calculated? Blood Cells Molecules and Diseases 2000; 26: 25–31 [discussion 32–26].

49.Fairbanks VF. Commentary: should whole-body red cell mass be measured or calculated. Blood Cells Molecules and Diseases 2000; 26: 32–36.

50.Hlad Jr. CJ & Tanz R. An analysis of technical errors in radioalbumin blood volume methods and presentation of a modified method. Journal of Laboratory and Clinical Medicine 1958; 52: 289–298.

51.Hinghofer-Szalkay H & Greenleaf JE. Continuous monitoring of blood volume changes in humans. Journal of Applied Physiology 1987; 63: 1003–1007.

52.Leslie WD, Dupont JO & Peterdy AE. Effect of obesity on red cell mass results. The Journal of Nuclear Medicine 1999; 40: 422–428.

53.Wasserman LR. The treatment of polycythemia. A panel discussion. Blood 1968; 32: 483–487.

54.Shih LY, Lee CT & Ou YC. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels. Experimental Hematology 1997; 25: 288–292.

55.Adamson JW, Fialkow PJ, Murphy S et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. The New England Journal of Medicine 1976; 295: 913–916.

56. Thiele J, Kvasnicka HM, Muehlhausen K et al. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001; 197: 77–84.

57.Temerinac S, Klippel S, Strunck E et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000; 95: 2569–2576.

58.BettinottiMP,OlsenA&StroncekD.Theuseofbioinformaticstoidentifythegenomicstructureofthe gene that encodes neutrophil antigen NB1, CD177. Clinical Immunology 2002; 102: 138–144.

59.Teofili L, Martini M, Luongo M et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. Journal of Clinical Oncology 2002; 20: 4249–4254.

60.Bodni RA, Sapia S, Galeano A & Kaminsky A. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry. Journal of the European Academy of Dermatology Venereology 2003; 17: 160–166.

61.Griesshammer M, Klippel S, Strunck E et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Annals of Hematology 2004; 83: 364–370.

62.Klippel S, Strunck E, Temerinac S et al. Quantification of PRV-1 mRNA distinguishes Polycythemia vera from secondary erythrocytosis. Blood 2003; 102: 3569–3574.

63.Kralovics R, Buser AS, Teo SS et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102: 1869–1871.

64.Alcocer L. Statins for everybody? New evidence on the efficacy and safety of the inhibitors of HMG Co-A reductase. American Journal of Therapeutics 2003; 10: 423–428.

65.Cilloni D, Carturan S, Gottardi E et al. Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. Blood 2004; 103: 2428 [author reply 2429].

66.FlorensaL,BessesC,ZamoraLetal.Endogenouserythroidandmegakaryocyticcirculatingprogenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood 2004; 103: 2427–2428.

67.PassamontiF,PietraD,MalabarbaLetal.ClinicalsignificanceofneutrophilCD177mRNAexpressio nin Ph-negative chronic myeloproliferative disorders. British Journal of Haematology 2004; 126: 650–656.

68.Zhang J, Pellagatti A, Campbell L et al. Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders. British Journal of Haematology 2004; 125: 17.

69.Tanaka C, Kuruma I & Kuramoto A. Histochemical demonstration of 5-hydroxytryptamine in platelets and megakaryocytes. Blood 1967; 30: 54–61.

70.Tranzer JP, Prada Md & Pletscher A. Storage of 5-hydroxytryptamine in megakaryocytes. The Journal of Cell Biology 1972; 52: 191–197.

71.Pareti FI, Gugliotta L, Mannucci L et al. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thrombosis and Haemostasis 1982; 47: 84–89.

72.Chauveau J, Fert V, Morel AM & Delaage MA. Rapid and specific enzyme immunoassay of serotonin. Clinical Chemistry 1991; 37: 1178–1184.

73.Maurer-SpurejE,DykerKSpurejE,DykerKSpurejE,DykerK,GahlWA&DevineDV. Anovel immunocytochemicalassayforthedetection of serotonin in platelets. British Journal of Haematology 2002; 116: 604–611.

74.Zerbinati P, Randi ML, Rossi C et al. Two methods for intraplatelet serotonin evaluation—their use in thrombocytosis. Clin Appl Thromb Hemost 1997; 3: 144–146.

75.Fabris F, Randi ML, Casonato A et al. Clinical significance of beta-thromboglobulin in patients with high platelet count. Acta Haematologica 1984; 71: 32–38.

76.Koch CA, Lasho TL & Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative

disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology 2004; 127: 34–39.

77.Reid CD. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Reviews 1987; 1: 133–140.

78.Prchal JF & Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. The New England Journal of Medicine 1974; 290: 1382.

79.Juvonen E, Partanen S & Ruutu T. Colony formation by megakaryocytic progenitors in essential thrombocythaemia. British Journal of Haematology 1987; 66: 161–164.

80.ZwickyC,TheilerL,ZbarenKetal.Thepredictivevalueofclonogenicstemcellassaysforthediagnosi s of polycythaemia vera. British Journal of Haematology 2002; 117: 598–604.

81.Partanen S, Juvonen E, Ikkala E & Ruutu T. Spontaneous erythroid colony formation in the differential diagnosis of erythrocytosis. European Journal of Haematology 1989; 42: 327–330.

82.Dobo I, Donnard M, Girodon F et al. Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. The Hematology Journal 2004; 5: 161–167.

83.ShihLY,LeeCT,SeeLCetal.Invitroculturegrowthoferythroidprogenitorsandserumerythropoietin assay in the differential diagnosis of polycythaemia. European Journal of Clinical Investigation 1998; 28: 569– 576.

84.Dobo I, Mossuz P, Campos L et al. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. The Hematology Journal 2001; 2: 396–403.

85.Horikawa Y, Matsumura I, Hashimoto K et al. Markedly reduced expression of platelet C-Mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031–4038.

86.Moliterno AR, Hankins WD & Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. The New England Journal of Medicine 1998; 338: 572–580.

87.YoonSY,LiCY&TefferiA.Megakaryocytec-Mplexpressioninchronicmyeloproliferativedisordersand the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. European Journal of Haematology 2000; 65: 170–174.

88.Le Blanc K, Andersson P & Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. British Journal of Haematology 2000; 108: 80–85.

89.Tefferi A, Yoon SY & Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 2000; 96: 771– 772.

90.Duensing S, Duensing A, Meran JG et al. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders. Molecular Pharmacology 1999; 52: 146–150.

91. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

92. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature, in press.

93. Kralovics R, Passamonti F, Buser AS et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. The New England Journal of Medicine 2005; 352: 1779–1790.

94. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

95.ZhaoR,XingS,LiZetal.IdentificationofanacquiredJAK2mutationinpolycythemiavera.The Journal of Biological Chemistry 2005;.

96.Steensma DP, Dewald GW, Lasho TL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both Atypical myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005;. doi10.1182/blood-2005-03-1183 [Blood First Edition Paper, prepublished online April 28, 2005].

97.Jones AV, Kreil S, Zoi K et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;. doi10.1182/blood-2005-03-1320 [Blood First Edition Paper, prepublished online May 26, 2005].

98.Lamy T, Devillers A, Bernard M et al. Inapparent polycythemia vera—an unrecognized diagnosis. American Journal of Medicine 1997; 102: 14–20.

99. Messinezy M, Westwood NB, El-Hemaidi I et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology 2002; 117: 47–53.

100. Mossuz P, Girodon F, Donnard M et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89: 1194–1198.

101. Diez-Martin JL, Graham DL, Petitt RM & Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clinic Proceedings 1991; 66: 287–299.

102.Andreasson B, Lo¨fvenberg E, Westin J. Management of patients with polycythaemia vera: Results of a survey among Swedish haematologists. European Journal of Haematology, in press, available online.

103.Galacteros F, Rosa R, Prehu MO et al. Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis. Nouvelle Revue franc¸aise d'He´matologie 1984; 26: 69–74.

104.Gordeuk VR, Stockton DW & Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica 2005; 90: 109–116.

105.Cario H. Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Annals of Hematology 2004;.

106.Vanuxem D, Guillot C, Fornaris E et al. Secondary polycythaemia in chronic respiratory insufficiency. Thorax 1977; 32: 317–321.

107.Smith JR & Landaw SA. Smokers' polycythemia. The New England Journal of Medicine 1978; 298: 6–10.

108.Hudgson P, Pearce JM & Yeates WK. Renal artery stenosis with hypertension and high haematocrit British Medical Journal 1967; 1: 18–21.

109.Matsuyama M, Yamazaki O, Horii K et al. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. Journal of Surgical Oncology 2000; 75: 197–202.

110.Ndububa DA, Ojo OS, Adetiloye VA et al. The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. European Journal of Gastroenterol and Hepatology 1999; 11: 1401–1404.

111.Wiesener MS, Seyfarth M, Warnecke C et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99: 3562–3565.

112.Skultety FM, Sorrell MF & Burklund CW. Hemangioblastoma of the cerebellum associated with erythrocytosis and an unusual blood supply. Case report. Journal of Neurosurgery 1970; 32: 700–705.

113.Weinstein RS. Parathyroid carcinoma associated with polycythemia vera. Bone 1991; 12: 237–239.

114.SuzukiM,TakamizawaS,NomaguchiKetal.Erythropoietinsynthesisbytumourtissuesinapatient with uterine myoma and erythrocytosis. British Journal of Haematology 2001; 113: 49–51.

115.Jermanovich NB. Polycystic kidney disease and polycythemia vera. Occurrence in a patient receiving hemodialysis. Archives of Internal Medicine 1983; 143: 1822–1823.

116.Bruneval P, Sassy C, Mayeux P et al. Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood 1993; 81: 1593–1597.

117.Spivak JL. Erythropoietin use and abuse: When physiology and pharmacology collide. Advances in Experimental Medicine and Biology 2001; 502: 207–224.

118.Dickerman RD, Pertusi R, Zachariah NY & Schaller F. Androgen-induced erythrocytosis. American Journal of Hematology 1998; 59: 263–264.

119.Wickre CG, Norman DJ, Bennison A et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney International 1983; 23: 731–737.

120.GlicklichD,KapoianT,MianHetal.Effects of erythropoietin,angiotensinII,andangiotensin-converting enzyme inhibitor on erythroid precursors in patients with post transplantation erythrocytosis. Transplantation 1999; 68: 62–66.

121.Mrug M, Julian BA & Prchal JT. Angiotensin II receptor type 1 expression in erythroid progenitors: implications for the pathogenesis of postrenal transplant erythrocytosis. Seminars in Nephrology 2004; 24: 120–130.